Cyfuse Biomedical K.K. (TYO:4892)
Japan · Delayed Price · Currency is JPY 567.00
-3.00 (-0.53%)
Aug 27, 2026, 2:03 PM JST
Cyfuse Biomedical K.K. Revenue
Cyfuse Biomedical K.K. had revenue of 76.00M JPY in the quarter ending June 30, 2026, with 1,420.00% growth. This brings the company's revenue in the last twelve months to 305.00M, up 369.23% year-over-year. In the year 2025, Cyfuse Biomedical K.K. had annual revenue of 230.00M with 325.93% growth.
Revenue (ttm)
305.00M
Revenue Growth
+369.23%
P/S Ratio
18.62
Revenue / Employee
13.26M
Employees
23
Market Cap
5.68B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 230.00M | 176.00M | 325.93% |
| Dec 31, 2024 | 54.00M | -7.00M | -11.48% |
| Dec 31, 2023 | 61.00M | -313.00M | -83.69% |
| Dec 31, 2022 | 374.00M | -334.00M | -47.18% |
| Dec 31, 2021 | 708.00M | 571.00M | 416.79% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Soiken Holdings | 3.87B |
| CellSource | 3.67B |
| PRISM BioLab Co.,LTD | 737.27M |
| Chiome Bioscience | 615.15M |
| D. Western Therapeutics Institute | 247.00M |
| ADR Biomedical Holdings | 101.00M |
| Ribomic | 7.50M |
| Noile-Immune Biotech | 1.00M |